Mads Krogsgaard Thomsen
Mads Krogsgaard Thomsen is a Danish scientist, businessman, and CEO of the Novo Nordisk Foundation.
Mads Krogsgaard Thomsen
Mads Krogsgaard Thomsen is a Danish scientist, businessman, and CEO of the Novo Nordisk Foundation.
The Novo Nordisk Foundation is an international foundation that supports scientific, humanitarian, and social causes, with a focus on research and development. It is the largest endowment in the world, with a current net worth of nearly 100 billion USD.
Mads Krogsgaard Thomsen is the former Head of Research and Development, and Chief Scientific Officer at the Danish multinational pharmaceutical company Novo Nordisk. Over the years, he was responsible for the research and development of 20 medical products, particularly within diabetes treatment. He spearheaded the optimisation of insulin analogues and the ground-breaking development of GLP-1. His efforts contributed to Novo Nordisk’s leading role as a diabetes medication and device manufacturer, with exports to over 180 countries.
Throughout his decorated career, he served on the Board of the Technical University of Denmark, Symphogen A/S, and BB Biotech AG. He also served as President of the Danish Academy of Technical Sciences, and Chairman of the Board of the Steno Diabetes Centre. To add, he was Chairman of the Board of the University of Copenhagen, where he is also an adjunct professor of Pharmacology, and where he received his PhD in 1991. Originally, he is a trained veterinarian and holds a DSc.
View bioClose